We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+8.51%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.91B
AUM Growth
+$65M
Cap. Flow
-$41.1M
Cap. Flow %
-1.41%
Top 10 Hldgs %
62.63%
Holding
44
New
12
Increased
5
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$99.7M
2
MRK icon
Merck
MRK
+$77.3M
3
GILD icon
Gilead Sciences
GILD
+$64.5M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$55.8M
5
WELL icon
Welltower
WELL
+$54.4M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$184M
2
BHC icon
Bausch Health
BHC
+$88.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$68.2M
4
MYGN icon
Myriad Genetics
MYGN
+$56.8M
5
BIIB icon
Biogen
BIIB
+$49M

Sector Composition

Rank Sector Weight
1 Healthcare 74.23%
2 Miscellaneous 13.6%
3 Technology 8.53%
4 Real Estate 3.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
26
Tectonic Therapeutic
TECX
$561M
$39.8M 1.36%
261,111
– –
RDUS
27
DELISTED
Radius Health, Inc.
RDUS
$31.3M 1.07%
1,500,000
-575,000
-28% -$12.1M
BLUE
28
DELISTED
bluebird bio
BLUE
$30.1M 1.03%
77,200
+15,440
+25% +$7.6M
PBYI icon
29
Puma Biotechnology
PBYI
$475M
$24.8M 0.85%
2,555,000
– –
MRTX
30
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$21.4M 0.73%
+125,000
New +$24.7M
TBIO
31
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$19M 0.65%
+1,150,000
New +$26.2M
INNV icon
32
InnovAge Holding
INNV
$1.5B
$16.8M 0.58%
+650,000
New +$16M
ABBV icon
33
CALL
AbbVie
ABBV
$465B
– –
-1,000,000
Closed -$107M
ANGO icon
34
AngioDynamics
ANGO
$649M
– –
-540,362
Closed -$8.28M
BHC icon
35
Bausch Health
BHC
$2.15B
– –
-4,250,000
Closed -$88.4M
BIIB icon
36
Biogen
BIIB
$32.2B
– –
-200,000
Closed -$49M
BMY icon
37
CALL
Bristol-Myers Squibb
BMY
$131B
– –
-2,000,000
Closed -$124M
CHRS icon
38
Coherus Oncology
CHRS
$199M
– –
-2,200,000
Closed -$38.2M
GILD icon
39
CALL
Gilead Sciences
GILD
$184B
– –
-2,500,000
Closed -$146M
CBIO
40
Crescent Biopharma
CBIO
$684M
– –
-22,000
Closed -$8.27M
SRPT icon
41
Sarepta Therapeutics
SRPT
$2.13B
– –
-400,000
Closed -$68.2M
WBA
42
CALL
DELISTED
Walgreens Boots Alliance
WBA
– –
-1,000,000
Closed -$39.9M
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-525,000
Closed -$11.6M
ALXN
44
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-1,175,000
Closed -$184M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Camber Capital Management held 44 positions worth $2.91B, up 2.3% from $2.85B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Camber Capital Management's Q1 2021 filing shows 12 new, 5 increased, 8 reduced and 12 closed positions. Its largest new stake was Zimmer Biomet: 643,750 shares worth $100M. The largest sale was Alexion Pharmaceuticals, an estimated $184M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 77% a quarter earlier, followed by Miscellaneous and Technology.

  • Camber Capital Management's largest Q1 2021 buy was Zimmer Biomet: 643,750 shares worth $100M.
  • Camber Capital Management added most to Walgreens Boots Alliance in Q1 2021, an estimated $37.1M increase.
  • Camber Capital Management's biggest Q1 2021 reduction was Myriad Genetics, cutting an estimated $56.8M.
  • Camber Capital Management fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $184M.
  • Camber Capital Management's ten largest holdings make up 63% of its $2.91B portfolio in Q1 2021.
  • Camber Capital Management opened 12 new positions and closed 12 in Q1 2021.
  • Camber Capital Management's portfolio value rose 2.3% quarter-over-quarter to $2.91B.

Based on Camber Capital Management's 13F filing for Q1 2021, filed 17 May 2021.